Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer

Yasuhiro Shinyo, Junichi Kodama, Hasengaowa, Tomoyuki Kusumoto, Yuji Hiramatsu

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objective. Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans (HS-GAG) and most of its biological functions are considered to be associated with this process. The aims of this study are to investigate its expression in cervical neoplasms. Methods. We investigated the expression of both the syndecan-1 core protein and cell-surface HS-GAG by immunohistochemistry in 53 cervical intraepithelial neoplasm (CIN), 19 microinvasive, 143 invasive cervical cancers, and 29 metastatic lymph node samples, and analyzed correlations with various clinicopathological features. Results. The progression of CIN to early invasive cancer was found to associate with reduced levels of both syndecan-1 and HS-GAG expression. In squamous cell carcinomas, HS-GAG expression was significantly lower in cases with lymph-vascular space invasion. Additionally, the overall survival rates for patients exhibiting low HS-GAG expression was significantly lower than patients exhibiting high HS-GAG expression (P = 0.019). Low HS-GAG expression in positive nodes was determined to be a disease-free and overall survival prognostic factor (P = 0.028 and P = 0.018, respectively). Conclusion. The loss of syndecan-1 and HS-GAG expression is an early event in cervical carcinogenesis. The loss of HS-GAG expression particularly in positive nodes can serve as an indicator of aggressive disease potential and poor prognosis in patients with invasive cervical cancer.

Original languageEnglish
Pages (from-to)776-783
Number of pages8
JournalGynecologic Oncology
Volume96
Issue number3
DOIs
Publication statusPublished - Mar 2005

Fingerprint

Cervical Intraepithelial Neoplasia
Heparitin Sulfate
Glycosaminoglycans
Uterine Cervical Neoplasms
Syndecan-1
Lymph
Disease-Free Survival
Extracellular Matrix
Blood Vessels
Squamous Cell Carcinoma
Membrane Proteins
Carcinogenesis
Survival Rate
Lymph Nodes
Immunohistochemistry

Keywords

  • Cervical cancer
  • Heparan sulfate
  • Syndecan-1

ASJC Scopus subject areas

  • Obstetrics and Gynaecology
  • Oncology

Cite this

Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer. / Shinyo, Yasuhiro; Kodama, Junichi; Hasengaowa; Kusumoto, Tomoyuki; Hiramatsu, Yuji.

In: Gynecologic Oncology, Vol. 96, No. 3, 03.2005, p. 776-783.

Research output: Contribution to journalArticle

Shinyo, Yasuhiro ; Kodama, Junichi ; Hasengaowa ; Kusumoto, Tomoyuki ; Hiramatsu, Yuji. / Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer. In: Gynecologic Oncology. 2005 ; Vol. 96, No. 3. pp. 776-783.
@article{cb167e2fab4946f4b1f9b078d8feae15,
title = "Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer",
abstract = "Objective. Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans (HS-GAG) and most of its biological functions are considered to be associated with this process. The aims of this study are to investigate its expression in cervical neoplasms. Methods. We investigated the expression of both the syndecan-1 core protein and cell-surface HS-GAG by immunohistochemistry in 53 cervical intraepithelial neoplasm (CIN), 19 microinvasive, 143 invasive cervical cancers, and 29 metastatic lymph node samples, and analyzed correlations with various clinicopathological features. Results. The progression of CIN to early invasive cancer was found to associate with reduced levels of both syndecan-1 and HS-GAG expression. In squamous cell carcinomas, HS-GAG expression was significantly lower in cases with lymph-vascular space invasion. Additionally, the overall survival rates for patients exhibiting low HS-GAG expression was significantly lower than patients exhibiting high HS-GAG expression (P = 0.019). Low HS-GAG expression in positive nodes was determined to be a disease-free and overall survival prognostic factor (P = 0.028 and P = 0.018, respectively). Conclusion. The loss of syndecan-1 and HS-GAG expression is an early event in cervical carcinogenesis. The loss of HS-GAG expression particularly in positive nodes can serve as an indicator of aggressive disease potential and poor prognosis in patients with invasive cervical cancer.",
keywords = "Cervical cancer, Heparan sulfate, Syndecan-1",
author = "Yasuhiro Shinyo and Junichi Kodama and Hasengaowa and Tomoyuki Kusumoto and Yuji Hiramatsu",
year = "2005",
month = "3",
doi = "10.1016/j.ygyno.2004.11.004",
language = "English",
volume = "96",
pages = "776--783",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "3",

}

TY - JOUR

T1 - Loss of cell-surface heparan sulfate expression in both cervical intraepithelial neoplasm and invasive cervical cancer

AU - Shinyo, Yasuhiro

AU - Kodama, Junichi

AU - Hasengaowa,

AU - Kusumoto, Tomoyuki

AU - Hiramatsu, Yuji

PY - 2005/3

Y1 - 2005/3

N2 - Objective. Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans (HS-GAG) and most of its biological functions are considered to be associated with this process. The aims of this study are to investigate its expression in cervical neoplasms. Methods. We investigated the expression of both the syndecan-1 core protein and cell-surface HS-GAG by immunohistochemistry in 53 cervical intraepithelial neoplasm (CIN), 19 microinvasive, 143 invasive cervical cancers, and 29 metastatic lymph node samples, and analyzed correlations with various clinicopathological features. Results. The progression of CIN to early invasive cancer was found to associate with reduced levels of both syndecan-1 and HS-GAG expression. In squamous cell carcinomas, HS-GAG expression was significantly lower in cases with lymph-vascular space invasion. Additionally, the overall survival rates for patients exhibiting low HS-GAG expression was significantly lower than patients exhibiting high HS-GAG expression (P = 0.019). Low HS-GAG expression in positive nodes was determined to be a disease-free and overall survival prognostic factor (P = 0.028 and P = 0.018, respectively). Conclusion. The loss of syndecan-1 and HS-GAG expression is an early event in cervical carcinogenesis. The loss of HS-GAG expression particularly in positive nodes can serve as an indicator of aggressive disease potential and poor prognosis in patients with invasive cervical cancer.

AB - Objective. Syndecan-1 binds to various extracellular matrix components via its heparan sulfate glycosaminoglycans (HS-GAG) and most of its biological functions are considered to be associated with this process. The aims of this study are to investigate its expression in cervical neoplasms. Methods. We investigated the expression of both the syndecan-1 core protein and cell-surface HS-GAG by immunohistochemistry in 53 cervical intraepithelial neoplasm (CIN), 19 microinvasive, 143 invasive cervical cancers, and 29 metastatic lymph node samples, and analyzed correlations with various clinicopathological features. Results. The progression of CIN to early invasive cancer was found to associate with reduced levels of both syndecan-1 and HS-GAG expression. In squamous cell carcinomas, HS-GAG expression was significantly lower in cases with lymph-vascular space invasion. Additionally, the overall survival rates for patients exhibiting low HS-GAG expression was significantly lower than patients exhibiting high HS-GAG expression (P = 0.019). Low HS-GAG expression in positive nodes was determined to be a disease-free and overall survival prognostic factor (P = 0.028 and P = 0.018, respectively). Conclusion. The loss of syndecan-1 and HS-GAG expression is an early event in cervical carcinogenesis. The loss of HS-GAG expression particularly in positive nodes can serve as an indicator of aggressive disease potential and poor prognosis in patients with invasive cervical cancer.

KW - Cervical cancer

KW - Heparan sulfate

KW - Syndecan-1

UR - http://www.scopus.com/inward/record.url?scp=13844296897&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=13844296897&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2004.11.004

DO - 10.1016/j.ygyno.2004.11.004

M3 - Article

C2 - 15810155

AN - SCOPUS:13844296897

VL - 96

SP - 776

EP - 783

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 3

ER -